Winnipeg – TheNewswire - [April 2nd, 2024]. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to provide an interim update on the recently completed human trial at The Ottawa Hospital where Cytophage bacteriophages were used to treat a patient with an antibiotic-resistant prosthetic joint infection (see press release from March 1st, 2024). The patient had previously undergone 15 surgeries and was facing the potential amputation of her leg at the waist. She was treated with Cytophage phages for several weeks, via both direct injection and through an IV line, and the Company is happy to report that according to her physician, infectious diseases clinician-scientist Dr. Marisa Azad (Principal Investigator), her condition is steadily improving with inflammation in her body decreasing.

As this is the first time a joint replacement infection has been treated with a bacteriophage in Canada, this landmark treatment has caught the attention of national news media with both CTV and CBC reporting on the phage trial in several segments. Media segments published to date include:

• CBC The National: “Experimental treatment using viruses helps woman avoid amputation” 

• CTV National News: ‘Phage’ Therapy in Canada  

• CBC News: 'This was my last resort,' Ottawa-area woman says of experimental phage therapy to treat infection 

• CTV Winnipeg: 'This is why we're here': A Winnipeg biotech company's role in a new treatment used in Canada 

Dr. Azad received special approval from Health Canada for this single subject clinical trial. Cytophage is expecting to share additional information on this trial with the public as permitted.

Cytophage CEO Dr. Steven Theriault commented: “It has truly been a momentous 2024 for Cytophage. We are incredibly proud of our team who has been able to develop and provide this therapy. Now that this trial is gaining so much attention from the news media, there is a much larger spotlight on Cytophage, which became the first Canadian phage company to go public.”

In addition to the recent media coverage on Cytophage, CEO Dr. Theriault continues to be a leading voice on bacteriophage applications within the scientific community. At an AMR Workshop on April 1st at the 2024 World Vaccine Congress in Washington, DC, Dr. Theriault presented on the topic “The application of phages to treat bacterial infections”. Cytophage is the only publicly traded bacteriophage company in North America with a stated focus on bacteriophage solutions for both animal health and human health.

For further information please contact:

Heather Medwick

Chief Operating Officer

heather@cytophage.com

431 388 8873

Cytophage Investor Alerts: https://cytophage.com/subscribe/

About CytophageTechnologies

Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are

described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.